- Home
- NUVL vs CELH Comparison
NUVL vs CELH Comparison
Compare NUVL & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CELH
- Stock Information
- Founded
- NUVL 2017
- CELH 2004
- Country
- NUVL United States
- CELH United States
- Employees
- NUVL N/A
- CELH N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- NUVL Health Care
- CELH Consumer Staples
- Exchange
- NUVL Nasdaq
- CELH Nasdaq
- Market Cap
- NUVL 5.5B
- CELH 5.3B
- IPO Year
- NUVL 2021
- CELH N/A
- Fundamental
- Price
- NUVL $79.49
- CELH $32.62
- Analyst Decision
- NUVL Strong Buy
- CELH Strong Buy
- Analyst Count
- NUVL 11
- CELH 18
- Target Price
- NUVL $112.36
- CELH $48.94
- AVG Volume (30 Days)
- NUVL 420.4K
- CELH 12.4M
- Earning Date
- NUVL 03-04-2025
- CELH 02-20-2025
- Dividend Yield
- NUVL N/A
- CELH N/A
- EPS Growth
- NUVL N/A
- CELH N/A
- EPS
- NUVL N/A
- CELH 0.45
- Revenue
- NUVL N/A
- CELH $1,355,630,000.00
- Revenue This Year
- NUVL N/A
- CELH $5.08
- Revenue Next Year
- NUVL N/A
- CELH $15.38
- P/E Ratio
- NUVL N/A
- CELH $72.49
- Revenue Growth
- NUVL N/A
- CELH 2.85
- 52 Week Low
- NUVL $61.80
- CELH $21.10
- 52 Week High
- NUVL $113.51
- CELH $99.62
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- CELH 72.79
- Support Level
- NUVL $77.84
- CELH $22.25
- Resistance Level
- NUVL $85.21
- CELH $26.22
- Average True Range (ATR)
- NUVL 3.78
- CELH 1.32
- MACD
- NUVL -0.46
- CELH 0.96
- Stochastic Oscillator
- NUVL 12.08
- CELH 86.36
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.